Emergent Biosolutions (EBS)
(Delayed Data from NYSE)
$9.35 USD
+0.41 (4.59%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $9.23 -0.12 (-1.28%) 7:58 PM ET
2-Buy of 5 2
B Value C Growth F Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$9.35 USD
+0.41 (4.59%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $9.23 -0.12 (-1.28%) 7:58 PM ET
2-Buy of 5 2
B Value C Growth F Momentum D VGM
Zacks News
3 Reasons Why Growth Investors Shouldn't Overlook Emergent Biosolutions (EBS)
by Zacks Equity Research
Emergent Biosolutions (EBS) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Emergent Biosolutions (EBS) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Emergent Biosolutions (EBS) closed the most recent trading day at $97.97, moving +1.01% from the previous trading session.
Is Emergent Biosolutions (EBS) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (EBS) Outperforming Other Medical Stocks This Year?
Company News for Dec 31, 2020
by Zacks Equity Research
Companies In The News Are: MKC, EBS, FOXA, AAPL
Emergent Biosolutions (EBS) Down 14.7% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Emergent Biosolutions (EBS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Is Emergent BioSolutions (EBS) a Good Stock to Pick Now?
by Zacks Equity Research
Is Emergent BioSolutions (EBS) a great pick from the value investor's perspective right now? Read on to know more.
Arena (ARNA) Q3 Earnings Top, Stock Down on Eczema Study Data
by Zacks Equity Research
Arena Pharmaceuticals (ARNA) beats bottom-line estimates for third-quarter 2020. Mid-stage atopic dermatitis study on etrasimod fails to meet primary endpoint but phase III study may start soon.
Deciphera (DCPH) Reports Narrower-Than-Expected Loss in Q3
by Zacks Equity Research
Deciphera (DCPH) reports a narrower-than-expected loss and sales beat estimates in the third quarter of 2020.
Iovance (IOVA) Q3 Earnings Beat Estimates, Pipeline in Focus
by Zacks Equity Research
Iovance's (IOVA) third-quarter earnings beat estimates. The company is progressing well with development of its lead pipeline candidate.
Emergent (EBS) Beats on Q3 Earnings, Tapers '20 Sales View
by Zacks Equity Research
Emergent (EBS) beats on earnings in Q3 while revenues miss estimates. Total product sales fall year over year and the company tightens its revenue guidance. Stock slides in after-hours trading.
BioMarin (BMRN) Beats on Q3 Earnings, Lowers Sales View
by Zacks Equity Research
BioMarin (BMRN) beats estimates for both earnings and sales in the third quarter. The company lowers its sales guidance for 2020.
Global Blood (GBT) Q3 Loss Wider Than Expected, Sales Miss
by Zacks Equity Research
Global Blood (GBT) reports a wider-than-expected loss and misses sales estimates in the third quarter of 2020.
Amicus' (FOLD) Q3 Loss Wider Than Expected, Revenues Beat
by Zacks Equity Research
Amicus (FOLD) reports a wider-than-expected loss but sales beat estimates in the third quarter of 2020.
Sarepta (SRPT) Q3 Loss Widens Y/Y, Revenues Beat Estimates
by Zacks Equity Research
Sarepta (SRPT) Q3 revenues increase year over year.
Clovis (CLVS) Q3 Earnings Top, Sales Show Coronavirus Impact
by Zacks Equity Research
Clovis (CLVS) reports mixed third-quarter 2020 results. Sales of the company's sole marketed drug, Rubraca, decline sequentially. Shares plunge.
Emergent Biosolutions (EBS) Q3 Earnings Top Estimates
by Zacks Equity Research
Emergent Biosolutions (EBS) delivered earnings and revenue surprises of 6.83% and -14.75%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Zoetis' (ZTS) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Zoetis (ZTS) beats earnings and sales estimates in the third quarter. The company raises 2020 guidance.
bluebird (BLUE) Q3 Loss Narrower Than Expected, Sales Miss
by Zacks Equity Research
bluebird (BLUE) reports a narrower-than-expected loss and misses sales estimates in the third quarter of 2020.
Perrigo (PRGO) Q3 Earnings Beat, Revenues Miss, Stock Up
by Zacks Equity Research
Perrigo (PRGO) reports decent third-quarter 2020 results. U.S. consumer self-care segment drives sales. Recovery in other two segments encouraging.
Zoetis (ZTS) in Focus: Stock Moves 6.9% Higher
by Zacks Equity Research
Zoetis (ZTS) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
Allogene (ALLO) Q3 Earnings Top Estimates, Pipeline Progresses
by Zacks Equity Research
Allogene (ALLO) reports no revenues for the third quarter of 2020.
Vaxart (VXRT) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
During Vaxart's (VXRT) impending third-quarter conference call, investors will keep tabs of its progress with its oral COVID-19 vaccine candidate VXA-CoV2-1.
Apellis Pharmaceuticals' (APLS) Q3 Loss Wider Than Expected
by Zacks Equity Research
Apellis (APLS) reports a wider-than-expected loss in the third quarter of 2020.
Bayer's (BAYRY) Q3 Earnings & Sales Miss Estimates, Down Y/Y
by Zacks Equity Research
Bayer (BAYRY) misses both earnings and sales estimates in the third quarter of 2020.
Horizon (HZNP) Q3 Earnings Top Estimates, Tepezza Drives Sales
by Zacks Equity Research
Horizon (HZNP) beats both earnings and sales estimates in the third quarter of 2020.